Welch Group LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 191,285 shares of the company’s stock after buying an additional 6,761 shares during the quarter. Johnson & Johnson comprises approximately 2.9% of Welch Group LLC’s holdings, making the stock its 18th largest position. Welch Group LLC’s holdings in Johnson & Johnson were worth $23,211,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in JNJ. Financial Gravity Wealth Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $105,000. WP Advisors LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $108,000. FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $117,000. Live Your Vision LLC lifted its holdings in shares of Johnson & Johnson by 58.3% in the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after buying an additional 502 shares during the period. Finally, Signition LP acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $204,000. 66.60% of the stock is owned by institutional investors.
In other news, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.
Shares of NYSE JNJ opened at $142.57 on Wednesday. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.32. The firm has a market cap of $377.43 billion, a PE ratio of 19.53, a P/E/G ratio of 2.20 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same period in the prior year, the business posted $1.90 earnings per share. Johnson & Johnson’s revenue was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.53%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is 49.32%.
COPYRIGHT VIOLATION WARNING: “Welch Group LLC Buys 6,761 Shares of Johnson & Johnson (JNJ)” was originally published by Week Herald and is owned by of Week Herald. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://weekherald.com/2018/11/07/welch-group-llc-buys-6761-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Why do companies issue stock splits?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.